Abstract
Dendritic cells (DC) are unique antigen-presenting cells that initiate and orchestrate adaptive immunity. Theoretically, cancer cells that express tumor-specific antigens can be destroyed by cytotoxic T cells. However, inherent antitumor responses are often not efficient, since tumor cells can mask their antigens and do not activate DC, an event required for the development of tumor antigen-specific cytotoxic T cell responses. Over a decade ago, the ex vivo preparation of autologous tumor antigen-loaded monocyte-derived DC vaccines as a novel potent anticancer strategy was launched. Phase I and II trials have been performed employing this strategy to treat several malignancies, such as B cell lymphoma, myeloma, melanoma, prostate, colon, ovarian, pancreatic, breast cancer, and renal cell carcinoma. So far, DC immunotherapy is well tolerated with little side or toxic effects. An issue of concern is the way DC are loaded with tumor antigens. An effective strategy is the loading of DC with tumor antigen through electroporation with tumor RNA. In this chapter, a comprehensive description of a protocol for loading of ex vivo-derived DC with total tumor RNA through electroporation is provided.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Erdmann M et al (2007) Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 30:663–674
Lesterhuis WJ et al (2010) Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30:5091–5097
Morse MA, Clay TM et al (2003) HER2 dendritic cell vaccines. Clin Breast Cancer 3(Suppl 4):S164–S172
Pezeshki AM et al (2011) Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses. J Immunol 187:74–81
Ashley DM et al (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177–1182
Boczkowski D et al (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472
Nair SK et al (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364–369
Brossart P et al (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61:6846–6850
Van Tendeloo VF et al (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56
O’Neill DW et al (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246
Porgador A et al (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918–2926
Sallusto F et al (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389–400
Ponsaerts P et al (2002) Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 169:1669–1675
Milano F et al (2007) An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. J Immunol Methods 321:94–106
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Milano, F., Krishnadath, K.K. (2014). Electroporation of Dendritic Cells with Autologous Total RNA from Tumor Material. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_9
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols